| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | Bolt Projects Holdings, Inc. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
| 27.02. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.02. | Bolt Projects to delist from Nasdaq, deregister with SEC | 3 | Seeking Alpha | ||
| 19.02. | Bolt Projects Holdings Announces Delisting From Nasdaq and SEC Deregistration | 1.188 | Business Wire | BERKELEY, Calif.--(BUSINESS WIRE)--Bolt Projects Holdings, Inc. (OTC Pink: BSLK, BSLKW), a developer of biomaterials for the beauty and personal care industry, today announced that its Board of Directors... ► Artikel lesen | |
| 05.01. | NASDAQ: Delisting von Bolt Projects Holdings nach Nichterfüllung der Eigenkapitalanforderungen | 1 | Investing.com Deutsch | ||
| 05.01. | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| BOLT PROJECTS Aktie jetzt für 0€ handeln | |||||
| 29.12.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.08.25 | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | 944 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| 17.07.25 | Pre-market Movers: Volcon, Bolt Projects, 22nd Century Group, Above Food Ingredients, Windtree Therapeutics | 1.128 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Volcon, Inc. (VLCN) is up over 161% at $24.11.
Bolt... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,160 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,810 | +1,91 % | Fate Therapeutics, Inc.: Fate Therapeutics Appoints Laura Hamill to Board of Directors | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Appointment of Davidson & Company as Its New Auditor | Toronto, Ontario--(Newsfile Corp. - May 22, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), is pleased to announce the appointment of Davidson... ► Artikel lesen | |
| TRINITY BIOTECH | 0,709 | +8,23 % | Trinity Biotech plc: Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations | - Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transformation... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 7,230 | +3,58 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| OVID THERAPEUTICS | 2,000 | +0,50 % | Ovid Therapeutics Inc. - 8-K, Current Report | ||
| CABALETTA BIO | 3,055 | +1,33 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| LONGEVERON | 0,790 | +0,44 % | Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) | ||
| VOR BIOPHARMA | 13,490 | -5,99 % | Vor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China | First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published... ► Artikel lesen | |
| QIAGEN | 31,765 | -0,67 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 42,690 | -7,46 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| TANGO THERAPEUTICS | 32,430 | +4,75 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,320 | +2,29 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| APOGEE THERAPEUTICS | 87,16 | -1,32 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| ABSCI | 7,145 | +5,00 % | Guggenheim hebt Kursziel für Absci auf 15 US-Dollar an - Potenzial durch Haarwuchsmittel |